HAART delays AIDS progression

Scientists at Johns Hopkins University and the New York Academy of Medicine say Highly Active Antiretroviral therapy delays the progression of AIDS.

Scientists at Johns Hopkins University and the New York Academy of Medicine say Highly Active Antiretroviral therapy delays the progression of AIDS.The HAART therapy also reduces mortality, but the optimal time to start it remains unknown.The study says the current guidelines for starting the therapy when counts are between 200/uL (200 per microliter) and 350/uL may be too low.The study, based on injection drug users, appears in the Sept. 15 issue of The Journal of Infectious Diseases.Cun-lin Wang and coworkers studied both HIV-positive and HIV-negative injection drug users to compare data in persons with the same mortality risk category.A total of 1,503 subjects were followed from 1997 to 2000. (Source: United Press, Sept 2004)